SCHEMBL20535596

SCHEMBL20535596

O=Cc1cc(Cl)c(Sc2ccc(Cl)c(Cl)c2)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 1/20 0.37
GRM5 P41594 2/20 0.36
HAO1 Q9UJM8 1/20 0.35
HTR1A P08908 1/20 0.35
HTR3A P46098 1/20 0.35
TERT O14746 1/20 0.35
ICAM1 P05362 1/20 0.34
SELE P16581 1/20 0.34
TDP1 Q9NUW8 2/20 0.33
LMNA P02545 2/20 0.33
EGLN1 Q9GZT9 1/20 0.33
MAPT P10636 1/20 0.33
RECQL P46063 1/20 0.33
PDE7A Q13946 1/20 0.33
AKT1 P31749 1/20 0.32
NOTUM Q6P988 1/20 0.32
RHEB Q15382 1/20 0.31
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20535594 0.78 ALDH1A1 (0.41) MEN1KMT2AALDH1A1GRM5HAO1
SCHEMBL20535403 0.75 TDP1 (0.53) MEN1KMT2AALDH1A1GRM5HAO1
SCHEMBL365661 0.75 EGLN1 (0.42) MEN1KMT2AALDH1A1GRM5ICAM1
SCHEMBL1965867 0.74 TDP1 (0.43) MEN1KMT2AALDH1A1TDP1LMNA
SCHEMBL20535987 0.72 HTR1A (0.39) MEN1KMT2AALDH1A1GRM5HAO1
SCHEMBL20535355 0.71
SCHEMBL20535357 0.71
SCHEMBL1808858 0.70 TDP1 (0.48) MEN1KMT2AALDH1A1TDP1LMNA
SCHEMBL12375092 0.70 TERT (0.43) MEN1KMT2AALDH1A1GRM5HAO1
SCHEMBL20535763 0.69 MEN1 (0.61) MEN1KMT2AALDH1A1TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 US disclosed
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 US disclosed
WO-2018191146-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF RHEB, KRAS, NRAS MEN1 254/4885KMT2A 2481/4885ALDH1A1 3621/4885
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof RHEB, GDI2, KRAS MEN1 169/4885KMT2A 3149/4885ALDH1A1 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.